News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Diaxonhit Agrees to Commercialize in Europe the XDx, Inc. AlloMa® Heart Transplant Test Following the Completion of Exclusive License Agreement


6/27/2013 10:04:21 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Diaxonhit (Paris:ALEHT), the leading French provider of specialty diagnostic solutions, and XDx, Inc., a U.S. molecular diagnostics company focused on non-invasive tests for transplantation and autoimmune disease, today announced that they have entered into a definitive exclusive license and distribution agreement to market and perform AlloMap Molecular Expression Testing (AlloMapĀ®) in Europe.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
XDx, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES